CT-P13, a Biosimilar of Anti-TNF-a for IBD CT-P13, a Biosimilar of Anti-TNF-a for IBD
Can CT-P13, a biosimilar of infliximab, be used safely in patients with inflammatory bowel diseases--and with comparable efficacy?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 25, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
UK CMA accuses Merck of breaking competition law with discount scheme
The UK Competition and Markets Authority (CMA) has accused US pharmaceutical company Merck Sharp& Dohme (MSD) of operating an anti-competitive discount scheme for its medicine Remicade. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 23, 2017 Category: Pharmaceuticals Source Type: news
UK watchdog accuses Merck of restricting biosimilar competition
Britain’s Competition and Markets Authority accused Merck‘s (NYSE:MRK) European unit, Merck Sharp & Dohme, of conducting an unfair discount scheme that it said was designed to restrict competition from biosimilar copies of the company’s drug, Remicade.
Remicade is an antibody drug used to treat rheumatoid arthritis, ulcerative colitis and Chron’s disease. It was the 1st antibody drug to face competition from copycat versions in the European markets. Biosimilar drugmakers, including South Korea’s Celltrion, have launched discounted products that are “similar” enough to Remicade to do the same job.
The ...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Wall Street Beat Merck Source Type: news
UK competition watchdog accuses Merck of obstructing biosimilars
LONDON (Reuters) - Britain's competition watchdog on Tuesday accused Merck& Co of operating an anti-competitive discount scheme for its medicine Remicade, designed to restrict competition from so-called biosimilar copies of the drug. (Source: Reuters: Health)
Source: Reuters: Health - May 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Janssen Biotech goes to court to block launch of Remicade biosimilar
Jansen Biotech is not going to let a second biosimilar version of its blockbuster rheumatoid arthritis drug Remicade hit pharmacy shelves in the United States without a fight.
The Horsham, Pa.-based subsidiary of Johnson& Johnson (NYSE: JNJ) has filed a patent infringement lawsuit with U.S. District Court in New Jersey to prevent Samsung Bioepis Co. Ltd. of South Korea from introducing Renflexis later this year.
Biosimilar products are different from generic drugs, which are chemically identical… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 19, 2017 Category: American Health Authors: John George Source Type: news
Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy
SEOUL (Reuters) - A unit of healthcare conglomerate Johnson& Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States. (Source: Reuters: Health)
Source: Reuters: Health - May 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Inflammatory Arthritis Stable after Switch to Biosimilar Infliximab (CME/CE)
(MedPage Today) -- Disease activity similar 1 year after non-medical switching in Denmark (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - May 14, 2017 Category: Geriatrics Source Type: news
' Fears Allayed' by Latest Infliximab Biosimilar Evidence'Fears Allayed' by Latest Infliximab Biosimilar Evidence
The biosimilar is noninferior to the originator infliximab in patients with stable Crohn ' s disease, ulcerative colitis, and other inflammatory conditions, two studies demonstrate.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 9, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Infliximab Biosimilar: Getting Closer to Interchangeability (CME/CE)
(MedPage Today) -- New studies show no differences in patients who switch (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 9, 2017 Category: Dermatology Source Type: news
Renflexis (Infliximab-abda Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 4, 2017 Category: Drugs & Pharmacology Source Type: news
Biosimilars Take Center Stage at Digestive Disease Week Biosimilars Take Center Stage at Digestive Disease Week
New phase 3 data comparing the efficacy and safety of infliximab with its biosimilar will be among the major research findings presented at Digestive Disease Week.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 3, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Samsung Bioepis receives FDA approval for Renflexis across all eligible indications
Samsung Bioepis has received the US Food and Drug Administration (FDA) approval for its biosimilar referencing Remicade (infliximab), Renflexis (infliximab-abda), across all eligible indications. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 24, 2017 Category: Pharmaceuticals Source Type: news
FDA Approves Second Biosimilar to Remicade (FREE)
By Kristin J. Kelley
Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH
The FDA late last week OK ' d the second … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 24, 2017 Category: Primary Care Source Type: news
FDA approves Samsung Bioepis' copy of J & J's Remicade: company
SEOUL (Reuters) - South Korea's Samsung Bioepis Co Ltd said on Saturday the U.S. Food and Drug Administration approved its copy of Johnson& Johnson's rheumatoid arthritis drug Remicade, the first drug developed by the Samsung Group unit approved in the United States. (Source: Reuters: Health)
Source: Reuters: Health - April 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
FDA approves 2nd near-copy of Remicade for immune disorders
Federal regulators have approved another alternative version of Remicade, an expensive injected drug widely used for rheumatoid arthritis and other immune system disorders (Source: ABC News: Health)
Source: ABC News: Health - April 21, 2017 Category: Consumer Health News Tags: Health Source Type: news
